Leukemias

Elias Jabbour MD and Farhad Ravandi MD review data from key leukemia presentations at the 2016 American Society of Hematology Annual Meeting.

Share

Program Content

Activities

  • Vadastuximab Talirine in AML
    Addition of Vadastuximab Talirine to 7 + 3 Induction Therapy for Newly Diagnosed AML: Phase Ib Dose-Escalation Trial
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 05, 2016

    Expires: December 04, 2017

  • TOWER: Blinatumomab QoL
    Phase III TOWER Substudy: Blinatumomab Shows Health-Related QoL Benefit vs Chemotherapy in R/R Ph- B-Precursor ALL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 06, 2016

    Expires: December 05, 2017

  • ABL001 in TKI-Resistant CML
    Phase I ABL001X2101: Novel BCR-ABL1 Inhibitor ABL001 Safe With Promising Activity in TKI-Resistant Chronic-Phase CML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 07, 2016

    Expires: December 06, 2017

  • INO + Mini-HCVD in ALL
    Inotuzumab Ozogamicin Plus Reduced-Intensity Chemotherapy Active in Untreated Older Patients With ALL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 07, 2016

    Expires: December 06, 2017

  • SGN-CD33A + HMA in Untreated AML
    Vadastuximab Talirine + Hypomethylating Agents Active and Well Tolerated in Untreated Older Patients With AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 08, 2016

    Expires: December 07, 2017

  • Vorinostat in Untreated AML
    Phase III SWOG S1203: Idarubicin + High-Dose Cytarabine ± Vorinostat vs Standard Therapy in Newly Diagnosed AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 08, 2016

    Expires: December 07, 2017

  • ELIANA: CTL019 in R/R ALL
    ELIANA: CTL019 Shows High CR Rate in Pediatric/Young Adult Patients With Relapsed/Refractory B-Cell ALL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2016

    Expires: December 08, 2017

  • TKI Cessation in CML
    Phase III EURO-SKI: Cessation of TKI Therapy Safe, Feasible for Pts Who Achieve Deep Molecular Response
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2016

    Expires: December 08, 2017

  • Ponatinib + Hyper-CVAD in Ph+ ALL
    Ponatinib Plus Hyper-CVAD Active as Frontline Therapy in Ph+ ALL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2016

    Expires: December 11, 2017

  • Downloadable Slideset
    Leukemias
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2016

    Expires: December 19, 2017

Provided by

ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen